Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | FADS1 | O60427 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12743181 | 0.88 | FADS1 (0.51) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL13734965 | 0.87 | MEN1 (0.63) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL21377414 | 0.87 | MEN1 (0.63) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL28360251 | 0.87 | RXFP1 (0.48) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL29910146 | 0.87 | RXFP1 (0.48) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL28032815 | 0.87 | MEN1 (0.63) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL11090583 | 0.86 | HDAC1 (0.45) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL11090585 | 0.86 | HDAC1 (0.45) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL11090579 | 0.86 | HDAC1 (0.45) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL13735757 | 0.86 | MEN1 (0.47) | MEN1KMT2AHDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137547-B | Heterocyclic compounds useful as TNF alpha modulators | 百时美施贵宝公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-108137547-A | It can be used as the heterocyclic compound of TNF α conditioning agent | 百时美施贵宝公司 | 2018-06-08 | — | — | CN | disclosed |
| EP-2170834-B1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES | ABBVIE INC (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8110572-B2 | Inhibitors of protein kinases | ABBOTT LABORATORIES (US) | 2012-02-07 | — | — | US | disclosed |
| EP-2170834-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES | Abbott Laboratories (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090054430-A1 | Inhibitors of Protein Kinases | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2009012312-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054430-A1 | Inhibitors of Protein Kinases | AURKC, AURKB, PLK1 | MEN1 950/4885KMT2A 1632/4885HDAC3 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.